Representatives for the musician clarified the nature of his hospitalization after rumors spread online that he was receiving ...

The Who has played 'Won't Get Fooled Again' with five drummers, and we're taking a look at their drum solo and Roger Daltrey's primal screams.

Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline ...

BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class. The Nasdaq-listed company – which is planning to rebrand as BeOne ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on PD-1xVEGF bispecific ivonescimab that is estimated to be worth as much ...

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a failed clinical trial.

The WHO has recommended Gilead's twice-yearly HIV PrEP drug lenacapavir, calling it 'transformational', but there are concerns about patient access.

3 Littler is eyeing World Matchplay Darts glory Credit: Getty Luke Humphries won the Phil Taylor Trophy for the first time last year, beating Michael van Gerwen 18–15 in the final.

Roche is moving its antibiotic zosurabalpin into phase 3 for CRAB, potentially a big step forward in the fight against antimicrobial resistance ...

Roche has added a phase 3 trial of trontinemab, hoping to show it can delay or prevent progression to Alzheimer's symptoms in preclinical patients.

The CHMP has advised against EU approval of Eli Lilly's Alzheimer's drug Kisunla, potentially handing an advantage to Eisai/Biogen's rival drug.

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion.